Type 1 diabetes immunotherapy: is the glass half empty or half full?

Kevan C Herold; Jeffrey A Bluestone

doi:10.1126/scitranslmed.3002981

Type 1 diabetes immunotherapy: is the glass half empty or half full?

Sci Transl Med. 2011 Aug 10;3(95):95fs1. doi: 10.1126/scitranslmed.3002981.

Authors

Kevan C Herold¹, Jeffrey A Bluestone

Affiliation

¹ Departments of Immunobiology and Internal Medicine, Yale University, New Haven, CT 06511, USA.

PMID: 21832236
DOI: 10.1126/scitranslmed.3002981

Abstract

Reevaluation of clinical data from the recent failed immunotherapy trials suggests that researchers should continue the quest to cure type 1 diabetes with immune therapies.

MeSH terms

Diabetes Mellitus, Type 1 / drug therapy
Diabetes Mellitus, Type 1 / immunology*
Diabetes Mellitus, Type 1 / therapy*
Humans
Hypoglycemic Agents / therapeutic use
Immunotherapy*

Substances

Hypoglycemic Agents